AnaSCI - Fitness Evolved

Buy Needles and Syringes with NO PRESCRIPTION   Synthetek Muscle Building And Fat Loss Products   Cheap Pure Supplements


  Synthetek Syntherol  
Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products   Largest Selection of Bodybuilding Products

User CP FAQ Members List Calendar New Posts Quick Links Log Out

AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved  AnaSCI Fitness Evolved


Automatic Translations (Powered by Yandex):
Albanian Belarusian Catalan Czech Danish Dutch English Estonian Finnish French German Greek Hungarian Italian Latvian Lithuanian Macedonian Norwegian Portuguese Russian Slovak Slovenian Spanish Swedish Turkish Ukrainian

Go Back   Anabolic Steroids Discussion and Bodybuilding Forum > Peptides & Growth Forum > Peptides & Human Growth Factors

Thread Tools Display Modes
AnaSCI VET / Donating Member
PRIDE's Avatar
Posts: 1,675
Join Date: Apr 2009
Tesamorelin - 10-11-2011, 08:10 PM


Tesamorelin is a possible treatment for muscle wasting.
Theratechnologies, a Canada-based developer of therapeutic peptide products, has started screening of patients in a Phase 2 trial to assess tesamorelin as a treatment for muscle wasting in patients with chronic obstructive pulmonary disease (COPD).

Tesamorelin is a growth hormone-releasing factor (GRF) analogue that induces growth hormone production and its anabolic properties have led Theratechnologies to pursue its development in muscle wasting in patients with COPD as a second indication for the compound.

A previously concluded phase 2 trial in stable ambulatory COPD patients has demonstrated a statistically significant increase in lean body mass (LBM).

The study will evaluate the efficacy and safety of a daily administration of either a 2mg or 3mg dose of a new formulation of tesamorelin for a period of 26 weeks.

The double-blind, multi-center, placebo-controlled, ran***ized trial is expected to be conducted in 25 centers across US and Canada.

The company expects to enroll about 200 patients and the trial results are expected before the end of 2012.
Reply With Quote
AnaSCI VET / Donating Member
PRIDE's Avatar
Posts: 1,675
Join Date: Apr 2009
More - 10-11-2011, 08:13 PM

Brand Name: Egrifta
Other Name(s): TH9507
Drug Class: Opportunistic Infection and Other Drugs

Tesamorelin, also known as TH9507, is a type of medicine called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps control metabolism, body shape, and use of energy.

Indications and Usage
Tesamorelin was approved by the U.S. Food and Drug Administration (FDA) on November 10, 2010 for the treatment of lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other ab***inal organs (visceral body fat).

Dosage Form/Administration
Always take this medicine as your doctor instructs.

Dosage Forms and Strengths
Tesamorelin is given as a daily shot (injection).

Recommended Daily Dose
Tesamorelin has been studied in clinical trials as a once-daily 2-mg injection.

Possible Side Effects
Tesamorelin may cause side effects.

The following life-threatening or serious side effects have been reported. Contact your doctor immediately if you experience:

Sensory loss
Muscle weakness or pain
Wasting of muscle in the hands, legs, or feet
Diarrhea with fever and dehydration
Loss of mobility
Congestive heart failure
Rash at the injection site
Joint pain
Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -4. The time now is 04:13 PM.

Copyright © 2003-2019 All rights reserved.